EXEL News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

EX

Mkt Cap

$15.41B

Volume

2.01M

Next Earnings

November 3rd

Loading chart

EX

EXELExelixis Inc

EXEL

Pay with—

Available Balance0.00

EX

Mkt Cap

$15.42B

Volume

2.01M

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

2 Under-the-Radar Stocks to Buy and HoldThe article recommends two underrated biotech stocks: Axsome Therapeutics, which is experiencing strong growth with its drug Auvelity (51% YoY sales growth) and has a promising pipeline including potential new indications; and Exelixis, a cancer-focused biotech with a dominant drug Cabometyx protected until at least 2030, plus encouraging progress on pipeline candidates like zanzalintinib.The Motley Fool · Oct 16, 2026

Why Exelixis (EXEL) is a Top Growth Stock for the Long-TermExelixis (EXEL), an oncology-focused biotechnology company, is highlighted as a stock to watch with a Zacks Rank #3 (Hold) and VGM Score of A. The company demonstrates strong growth potential with a Growth Style Score of A and forecasted year-over-year earnings growth of 15.9% for the current fiscal year, supported by recent upward analyst revisions.Zacks Investment Research · Oct 16, 2026

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates AgainExelixis (EXEL), a biomedical and genetics drug developer, has demonstrated a consistent pattern of beating earnings estimates over the last two quarters with an average surprise of 10.91%. The company's positive Earnings ESP of +2.44% combined with its Zacks Rank #3 (Hold) rating suggests another potential earnings beat is likely, as stocks with this combination historically beat consensus estimates nearly 70% of the time.Zacks Investment Research · Oct 15, 2026

Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify stocks with strong performance potential. The service combines value, growth, and momentum analysis to rate stocks, with historical data showing #1 Rank stocks averaging +23.8% annual returns since 1988. Exelixis (EXEL) is highlighted as a growth-focused biotech stock with a #3 Hold rating and Grade A VGM and Growth scores.Zacks Investment Research · Sep 30, 2026

Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth OpportunitiesThe bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.GlobeNewswire Inc. · Sep 30, 2026

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmKuehn Law is investigating whether officers and directors of EXELIXIS, Inc. breached fiduciary duties to shareholders through potential self-dealing. The firm is seeking long-term EXEL stockholders to participate in shareholder litigation, offering free consultations with no obligation.GlobeNewswire Inc. · Jul 29, 2026

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsightThe metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.GlobeNewswire Inc. · Jun 10, 2026

Prediction: This Stock Could Double By 2031Exelixis, a biotech company focused on cancer medicines, could potentially double by 2031. While its main product Cabometyx will face generic competition by early 2030, the company's promising pipeline candidate zanzalintinib could reach peak sales of $5 billion across multiple cancer indications, positioning it as a strong successor to drive future growth.The Motley Fool · May 15, 2026

Why Is Merck Stock Falling Tuesday?Merck & Co. and Eisai announced that their Phase 3 LITESPARK-012 trial failed to meet primary endpoints for a triplet therapy combining Keytruda, Lenvima, and Welireg for advanced clear cell renal cell carcinoma. The failure caused Merck shares to fall 4.08%. However, the FDA approved Merck's new HIV treatment Idvynso on the same day, and analysts suggest alternative treatment strategies may still be viable.Benzinga · Apr 21, 2026

The Best Healthcare Stocks to Buy With $50 Right NowThe article recommends three healthcare stocks trading under $50: Pfizer (PFE) at $27.45 with a low forward P/E of 9x and a strong oncology pipeline; Novo Nordisk (NVO) at $38.43 positioned to capitalize on the expanding weight-loss drug market with products like Wegovy; and Exelixis (EXEL) at $41.80, a focused oncology player with the successful Cabometyx therapy and promising pipeline candidates like zanzalintinib.The Motley Fool · Mar 18, 2026

to start trading

EX

EXELExelixis Inc

EXEL

Pay with—

Available Balance0.00

Your PositionYou don't own any EXEL yet.

Related Tickers

Earnings